Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
2015
Background
AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naive patients with metastatic clear cell renal cell carcinoma (mRCC).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
49
References
121
Citations
NaN
KQI